Skip to main content

insulin degludec (Tresiba®)


Status: In progress

Treatment of diabetes mellitus in adolescents and children from the age of 1 year.

Medicine details

Medicine name insulin degludec (Tresiba®)
Formulation 100 units/ml and 200 units/ml solution for injection
Reference number 5196

As above

Company Novo Nordisk Ltd
BNF chapter Endocrine system
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date 14/09/2022
Date of issue TBA
Follow AWTTC: